Actualité

Dernieres Publications
Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC
Detection of esophageal varices and prediction of hepatic decompensation in unresectable hepatocellular carcinoma using AI
Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data.
The « A-B-C » Classification Reveals Outcome Trajectories in Patients With Hepatocellular Carcinoma Under Atezolizumab/Bevacizumab.
Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC
Detection of esophageal varices and prediction of hepatic decompensation in unresectable hepatocellular carcinoma using AI
Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data.
The « A-B-C » Classification Reveals Outcome Trajectories in Patients With Hepatocellular Carcinoma Under Atezolizumab/Bevacizumab.

Nos dernières publications
Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC
Detection of esophageal varices and prediction of hepatic decompensation in unresectable hepatocellular carcinoma using AI
Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data.
The « A-B-C » Classification Reveals Outcome Trajectories in Patients With Hepatocellular Carcinoma Under Atezolizumab/Bevacizumab.
Atezolizumab-Bevacizumab in Very Elderly With Hepatocellular Carcinoma: Age Alone Is Not a Limiting Factor Except in ALBI Grade 3.
[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study
Patient and physician expectation’s regarding disease and treatment of advanced HCC: the prospective PERCEPTION1 study
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab.
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.

Nos derniers essais cliniques

CAPRIH : début en 2024

Cohorte institutionnelle. Cohorte multicentrique chez les patients ayant un cancer primiti hépatique rare Investigateur principal:...

IMMUNO-TH : début en 2024

Essai institutionnel Étude multicentrique ouverte de phase 2 testant l’atezolizumab bevacizumab après récidive d’un CHC...

Nos dernières rencontres

Journée du 10 décembre 2026

Description
Session du jeudi 10 décembre 2026
le programme
En savoir plus ...
Date: 2026-12-10

Journée soutenue par:

Journée du 25 juin 2026

Description
Session du jeudi 25 juin 2026
le programme
En savoir plus ...
Date: 2026-06-25

Journée soutenue par:

Pour les patients

Découvrez notre encyclopédie d’articles sur différents cas médicaux

explication pédagogique sur les maladies et les traitements

Newsletter

Restez informé des dernières nouvelles

Contactez nous

  • Paris, France
  • contact@parislivercancergroup.com
Pour les patients

Fermer